Skip Navigation
NIH HHS News Release Logo
National Institute of Allergy and
Infectious Diseases (NIAID)
http://www.niaid.nih.gov

FOR IMMEDIATE RELEASE
September 10, 2013, 6:30 pm Eastern Time

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

MEDIA AVAILABILITY
NIH Scientists Develop New Tests to Detect Drug-Resistant Malaria

Developed with French, Cambodian Researchers, Assays Can Monitor Resistance Spread, Screen New Drugs

WHAT:

Researchers have developed two tests that can discern within three days whether the malaria parasites in a given patient will be resistant or susceptible to artemisinin, the key drug used to treat malaria. The tests were developed by researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, working with French and Cambodian colleagues in Cambodia. They offer a more rapid, less costly advantage over current drug-responsiveness tests, which require malaria patients to be hospitalized for blood draws every six hours over the course of several days. In both tests, young parasites are briefly exposed to a high dose of artemisinin, mimicking the way parasites are exposed to the drug in people being treated for malaria, and their survival is measured 72 hours later.

The first test is conducted on blood taken from a malaria patient at the same time as the first dose of artemisinin-based combination drug therapy is administered. The test returns results in 72 hours and can predict whether the patient has slow-clearing, drug-resistant parasites. The researchers note that the simple, new test could be used for surveillance studies to monitor and map the emergence or spread of artemisinin-resistant malaria parasites. In the current study, researchers using this test detected artemisinin-resistant parasites at sites in Northern and Eastern Cambodia for the first time.

The second test is conducted on parasites grown in the laboratory. This test requires trained technicians to adapt parasites from a malaria patient to a laboratory culture, synchronize the life-stages of the parasites, and then apply the drug only to those that are three hours old or younger. This test will likely be most useful in future studies designed to elucidate the molecular basis of artemisinin resistance and to screen new malaria drugs.

The study was led by Rick Fairhurst, M.D., Ph.D., of the NIAID Laboratory of Malaria and Vector Research, and Didier Menard, Ph.D., of the Institut Pasteur du Cambodge, Cambodia.

ARTICLE:

B Witkowski et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. The Lancet Infectious Diseases DOI: 10.1016/S1473-3099(13)70252-4 (2013).

WHO:

NIAID Director Anthony S. Fauci, M.D., and Rick M. Fairhurst, M.D., Ph.D., Laboratory of Malaria and Vector Research, NIAID, are available to discuss this research.

CONTACT:

To schedule interviews, please contact Anne A. Oplinger, (301) 402-1663, aoplinger@niaid.nih.gov.


NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH...Turning Discovery Into Health ®

back to top


Last Updated September 10, 2013

Last Reviewed September 10, 2013